HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simon, P. Articles by Wolner, E. Search for Related Content PubMed PubMed Citation Articles by Simon, P. Articles by Wolner, E. Related Collections Cardiac - other Congenital - acyanotic Valve disease

Eur J Cardiothorac Surg 2003;23:1002-1006
© 2003 Elsevier Science NL

Early failure of the tissue engineered porcine heart valve SYNERGRAFT^TM in pediatric patients

^a Department of Cardiothoracic Surgery, AKH-University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria
^b Department of Surgery, AKH-University of Vienna, Vienna, Austria
^c Department of Pathology, AKH-University of Vienna, Vienna, Austria
^d Department of Pediatric Cardiology, AKH-University of Vienna, Vienna, Austria

Received 7 November 2002; received in revised form 21 January 2003; accepted 3 February 2003.

^* Corresponding author. Tel.: +43-1-40400-5620; fax: +43-1-40400-5640
e-mail: paul.simon{at}univie.ac.at

Objectives: The first tissue engineered decellularized porcine heart valve, Synergraft^TM (Cryolife Inc., USA) was introduced in Europe as an alternative to conventional biological valves. This is the first report of the rapid failure of these new grafts in a small series. Materials and methods: In 2001, 2 model 500 and 2 model 700 Synergraft^TM valves were implanted in four male children (age 2.5–11 years) in the right ventricular outflow tract as a root. Two patients had a Ross operation and two had a homograft replacement. Results: The cryopreserved Synergraft^TM valves appeared macroscopically unremarkable at implantation. Recovery from surgery was uneventful and good valve function was demonstrated postoperatively. Three children died, two suddenly with severely degenerated Synergraft^TM valves 6 weeks and 1 year after implantation. The third child died on the 7th day due to Synergraft^TM rupture. Subsequently the fourth graft was explanted prophylactically 2 days after implantation. Macroscopically all four grafts showed severe inflammation starting on the outside (day 2 explant) leading to structural failure (day 7 explant) and severe degeneration of the leaflets and wall (6 weeks and 1 year explant). Histology demonstrated severe foreign body type reaction dominated by neutrophil granulocytes and macrophages in the early explants and a lymphocytic reaction at 1 year. In addition significant calcific deposits were demonstrated at all stages. Surprisingly pre-implant samples of the Synergraft^TM revealed incomplete decellularization and calcific deposits. No cell repopulation of the porcine matrix occurred. Conclusion: The xenogenic collagen matrix of the Synergraft^TM valve elicits a strong inflammatory response in humans which is non-specific early on and is followed by a lymphocyte response. Structural failure or rapid degeneration of the graft occurred within 1 year. Calcific deposits before implantation and incomplete decellularization may indicate manufacturing problems. The porcine Synergraft^TM treated heart valves should not be implanted at this stage and has been stopped.

Key Words: Valve replacement • Congenital heart disease • Bioprosthesis • Tissue engineering • Matrix • Collagen

This article has been cited by other articles:

				R. A. Hopkins, A. L. Jones, L. Wolfinbarger, M. A. Moore, A. A. Bert, and G. K. Lofland Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 907 - 913. [Abstract] [Full Text] [PDF]

				F. J. Schoen Evolving Concepts of Cardiac Valve Dynamics: The Continuum of Development, Functional Structure, Pathobiology, and Tissue Engineering Circulation, October 28, 2008; 118(18): 1864 - 1880. [Abstract] [Full Text] [PDF]

				G. De Visscher, H. Blockx, B. Meuris, H. Van Oosterwyck, E. Verbeken, M.-C. Herregods, and W. Flameng Functional and biomechanical evaluation of a completely recellularized stentless pulmonary bioprosthesis in sheep. J. Thorac. Cardiovasc. Surg., February 1, 2008; 135(2): 395 - 404. [Abstract] [Full Text] [PDF]

				R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]

				J. E. Mayer Tissue Engineering for Cardiac Valve Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 1649 - 1656. [Full Text]

				P. M. Dohmen, A. Lembcke, S. Holinski, D. Kivelitz, J. P. Braun, A. Pruss, and W. Konertz Mid-Term Clinical Results Using a Tissue-Engineered Pulmonary Valve to Reconstruct the Right Ventricular Outflow Tract During the Ross Procedure Ann. Thorac. Surg., September 1, 2007; 84(3): 729 - 736. [Abstract] [Full Text] [PDF]

				D. Schmidt, U. A Stock, and S. P Hoerstrup Tissue engineering of heart valves using decellularized xenogeneic or polymeric starter matrices Phil Trans R Soc B, August 29, 2007; 362(1484): 1505 - 1512. [Abstract] [Full Text] [PDF]

				A. Vincentelli, F. Wautot, F. Juthier, O. Fouquet, D. Corseaux, S. Marechaux, T. Le Tourneau, O. Fabre, S. Susen, E. Van Belle, et al. In vivo autologous recellularization of a tissue-engineered heart valve: Are bone marrow mesenchymal stem cells the best candidates? J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 424 - 432. [Abstract] [Full Text] [PDF]

				K. Hayashida, K. Kanda, H. Yaku, J. Ando, and Y. Nakayama Development of an in vivo tissue-engineered, autologous heart valve (the biovalve): Preparation of a prototype model J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 152 - 159. [Abstract] [Full Text] [PDF]

				W. Li, W.-Y. Liu, D.-H. Yi, S.-Q. Yu, and Z.-X. Jin Histological/Biological Characterization of Decellularized Bovine Jugular Vein Asian Cardiovasc Thorac Ann, April 1, 2007; 15(2): 91 - 96. [Abstract] [Full Text] [PDF]

				T. Ota, S. Taketani, S. Iwai, S. Miyagawa, M. Furuta, M. Hara, E. Uchimura, Y. Okita, and Y. Sawa Novel Method of Decellularization of Porcine Valves Using Polyethylene Glycol and Gamma Irradiation Ann. Thorac. Surg., April 1, 2007; 83(4): 1501 - 1507. [Abstract] [Full Text] [PDF]

				J. O. Bohm, C. A. Botha, A. Horke, W. Hemmer, D. Roser, G. Blumenstock, F. Uhlemann, and J.-G. Rein Is the Ross operation still an acceptable option in children and adolescents? Ann. Thorac. Surg., September 1, 2006; 82(3): 940 - 947. [Abstract] [Full Text] [PDF]

				A. Vincentelli, F. Juthier, and B. Jude Reply to the editor. J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 737 - 737. [Full Text] [PDF]

				C. Stamm and G. Steinhoff When less is more: Go slowly when repopulating a decellularized valve in vivo! J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 735 - 737. [Full Text] [PDF]

				P. M. Dohmen and W. Konertz Results With Decellularized Xenografts Circ. Res., August 18, 2006; 99(4): e10 - e10. [Full Text] [PDF]

				S. Cebotari, A. Lichtenberg, I. Tudorache, A. Hilfiker, H. Mertsching, R. Leyh, T. Breymann, K. Kallenbach, L. Maniuc, A. Batrinac, et al. Clinical Application of Tissue Engineered Human Heart Valves Using Autologous Progenitor Cells Circulation, July 4, 2006; 114(1_suppl): I-132 - I-137. [Abstract] [Full Text] [PDF]

				A. Mol, M. C.M. Rutten, N. J.B. Driessen, C. V.C. Bouten, G. Zund, F. P.T. Baaijens, and S. P. Hoerstrup Autologous Human Tissue-Engineered Heart Valves: Prospects for Systemic Application Circulation, July 4, 2006; 114(1_suppl): I-152 - I-158. [Abstract] [Full Text] [PDF]

				U.A. Stock, I. Degenkolbe, T. Attmann, K. Schenke-Layland, S. Freitag, and G. Lutter Prevention of device-related tissue damage during percutaneous deployment of tissue-engineered heart valves J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1323 - 1330. [Abstract] [Full Text] [PDF]

				Reply. Ann. Thorac. Surg., May 1, 2006; 81(5): 1942 - 1943. [Full Text] [PDF]

				F. Juthier, A. Vincentelli, J. Gaudric, D. Corseaux, O. Fouquet, C. Calet, T. L. Tourneau, V. Soenen, C. Zawadzki, O. Fabre, et al. Decellularized heart valve as a scaffold for in vivo recellularization: Deleterious effects of granulocyte colony-stimulating factor J. Thorac. Cardiovasc. Surg., April 1, 2006; 131(4): 843 - 852. [Abstract] [Full Text] [PDF]

				K. J. Zehr, M. Yagubyan, H. M. Connolly, S. M. Nelson, and H. V. Schaff Aortic root replacement with a novel decellularized cryopreserved aortic homograft: Postoperative immunoreactivity and early results J. Thorac. Cardiovasc. Surg., October 1, 2005; 130(4): 1010 - 1015. [Abstract] [Full Text] [PDF]

				S. R. Meyer, J. Nagendran, L. S. Desai, G. R. Rayat, T. A. Churchill, C. C. Anderson, R. V. Rajotte, J. R.T. Lakey, and D. B. Ross Decellularization reduces the immune response to aortic valve allografts in the rat J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 469 - 476. [Abstract] [Full Text] [PDF]

				G. H.L. Tang, S. Fazel, R. D. Weisel, G. S. Van Arsdell, and R.-K. Li Cardiovascular Tissue Engineering Therapy: So Near, So Far? Ann. Thorac. Surg., June 1, 2005; 79(6): 1831 - 1833. [Full Text] [PDF]

				R. A. Hopkins Tissue Engineering of Heart Valves: Decellularized Valve Scaffolds Circulation, May 31, 2005; 111(21): 2712 - 2714. [Full Text] [PDF]

				E. Rieder, G. Seebacher, M.-T. Kasimir, E. Eichmair, B. Winter, B. Dekan, E. Wolner, P. Simon, and G. Weigel Tissue Engineering of Heart Valves: Decellularized Porcine and Human Valve Scaffolds Differ Importantly in Residual Potential to Attract Monocytic Cells Circulation, May 31, 2005; 111(21): 2792 - 2797. [Abstract] [Full Text] [PDF]

				R. W. Grauss, M. G. Hazekamp, F. Oppenhuizen, C. J. van Munsteren, A. C. Gittenberger-de Groot, and M. C. DeRuiter Histological evaluation of decellularised porcine aortic valves: matrix changes due to different decellularisation methods Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 566 - 571. [Abstract] [Full Text] [PDF]

				F. D. Affonso da Costa, P. M. Dohmen, D. Duarte, C. von Glenn, S. V. Lopes, H. H. Filho, M. B. Affonso da Costa, and W. Konertz Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the Ross operation Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 572 - 578. [Abstract] [Full Text] [PDF]

				J.F. M. Bechtel, J. Gellissen, A. W. Erasmi, M. Petersen, A. Hiob, U. Stierle, and H.-H. Sievers Mid-term findings on echocardiography and computed tomography after RVOT-reconstruction: comparison of decellularized (SynerGraft) and conventional allografts Eur. J. Cardiothorac. Surg., March 1, 2005; 27(3): 410 - 415. [Abstract] [Full Text] [PDF]

				F. J. Schoen and R. J. Levy Calcification of Tissue Heart Valve Substitutes: Progress Toward Understanding and Prevention Ann. Thorac. Surg., March 1, 2005; 79(3): 1072 - 1080. [Abstract] [Full Text] [PDF]

				C. Stamm, A. Khosravi, N. Grabow, K. Schmohl, N. Treckmann, A. Drechsel, M. Nan, K.-P. Schmitz, A. Haubold, and G. Steinhoff Biomatrix/Polymer Composite Material for Heart Valve Tissue Engineering Ann. Thorac. Surg., December 1, 2004; 78(6): 2084 - 2093. [Abstract] [Full Text] [PDF]

				H. Mertsching, T. Walles, and P. Macchiarini Replacement of the trachea with an autologous aortic graft Ann. Thorac. Surg., September 1, 2004; 78(3): 1132 - 1133. [Full Text] [PDF]

				W.-H. Zimmermann and T. Eschenhagen Tissue engineering of aortic heart valves Cardiovasc Res, December 1, 2003; 60(3): 460 - 462. [Full Text] [PDF]